Aarti Industries Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4q7g2q6bupmuwjk6oncw2lf6.pdf

Key Takeaways


The Quarter's Damage: What Happened and Why

Suyog Kotecha: "I think I would not say it has established as a firm trend. We see, of course, stray incidences where realizations have been taken up in the last few months. But I would still hesitate to characterize it as a generic trend."

Product Chain Health: Where the Pain and Promise Sit

SegmentTrendCommentary
Energy Applications (MMA)▬ Flattish volumesDemand strong but pricing under pressure from competition and falling RM; improving crack spreads expected to help; US tariff risk now added.
Agrochemical Intermediates▼ Pricing pressureVolumes picking up but intermediates lag downstream recovery; improvement needs both demand uptick and capacity absorption, a multi-quarter story.
Dyes, Pigments, Pharma▬ StableNo major deterioration flagged.
Polymers & Additives (ex-DCB)▲ Demand recoveryParts of the segment showing very good demand recovery.
DCB▼ Sharp weaknessUS automotive customers going through inventory liquidation and demand uncertainty; exports to US significantly lower YoY and QoQ; tariffs now add competitive pressure.
NCB▼ Volume declineDriven by strategic customer challenges and June operational issues at the nitrochlorobenzene unit; entirely domestic.
Suyog Kotecha: "We have a market leadership position globally in this product, and we would like to continue to maintain that. And we have the least cost position as far as our internal benchmarking exercise goes with respect to competition."

The Growth Bet: Zone-IV and New Capacity

Suyog Kotecha: "We are talking about historical five years back if you look at what was the AIL's margin profile, we are targeting to go back to those kind of margin levels with these new products coming in. So, 20% plus EBITDA kind of margin profile for most of these products."

Cost and Capital Discipline

Suyog Kotecha: "We are mindful of the global demand/supply balances and where should we allocate incremental capital going forward. At the same time, the projects which we have taken on, I think we are going through them while optimizing the design and the portfolio of those capex to ensure that we get best returns out of it."

China, Competition, and the Pricing Cycle

Suyog Kotecha: "It is fair to say we are talking about significant overcapacity and the demand/supply balancing will not happen with one year of demand growth." [15–16]

Guidance & Commitments

CommitmentSpecificsTimeline
Three-year EBITDA target₹1,800 croreFY26–28 (three-year horizon)
Zone-IV Phase-I commissioningMultipurpose plant and calcium chloride unitDecember 2025
Zone-IV remaining blocksFive additional blocks, phased commissioningJanuary to May 2026
Augene JV commissioningProject completion and start-upH1 CY26
Aarti Circularity operationsCommercial operations beginEarly FY27
FY26 capex ceilingBelow ₹1,000 croreFY26
Next year capex dropDramatic reduction from ~₹1,000 croreFY27
Net debt ceilingRemain roughly around ₹3,500 croreOngoing
Cost-saving program65–70% of ₹150–200 crore implementedWithin FY26
Solar cost initiative commissioningSolar component onlineNovember/December 2025
Hybrid cost initiative commissioningHybrid component onlineApril/May 2026
DCB volume recoverySecond-half recovery as customer inventory correction endsH2 FY26
US tariff mitigation planClarity on MMA and DCB mitigation actionsTwo to three weeks
New product margin profile20% plus EBITDA margin for most Zone-IV/MPP productsAs new capacity commercializes

Key Metrics

MetricQ1 FY26
Revenue₹1,867 cr, decline of 16% QoQ
EBITDA₹215 cr, decline of 19% QoQ
Profit After Tax₹43 cr
Exports₹950 cr
Capex₹280 cr; FY26 expected below ₹1,000 cr
Net debt~₹3,500 cr (peak level); reduction of ₹200–300 cr targeted in FY26
Inventory valuation loss₹30 cr
EBITDA impact from delayed shipments₹15–20 cr
Foreign exchange gain₹16 cr
MMA capacity~260 KTPA, scaled up from 200 KTPA
Nitrotoluene capacity45 KTPA, scaled up from 30 KTPA
Ethylation capacity30 KTPA, scaled up from 10 KTPA
US revenue exposure15–20% of revenues (direct exports)
July MMA exports~20,000–22,000 tons